Organogenesis (ORGO) Competitors

Organogenesis has higher revenue and earnings than Ironwood Pharmaceuticals. Organogenesis is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Ironwood Pharmaceuticals has a net margin of 33.36% compared to Organogenesis' net margin of -19.94%. Organogenesis' return on equity of -23.89% beat Ironwood Pharmaceuticals' return on equity.

Organogenesis has a beta of 1.27, meaning that its stock price is 27% more volatile than the broader market. Comparatively, Ironwood Pharmaceuticals has a beta of 0.21, meaning that its stock price is 79% less volatile than the broader market.

In the previous week, Ironwood Pharmaceuticals had 1 more articles in the media than Organogenesis. MarketBeat recorded 1 mentions for Ironwood Pharmaceuticals and 0 mentions for Organogenesis. Ironwood Pharmaceuticals' average media sentiment score of 0.74 beat Organogenesis' score of 0.00 indicating that Ironwood Pharmaceuticals is being referred to more favorably in the news media.

Organogenesis presently has a consensus target price of $4.33, indicating a potential upside of 225.81%. Ironwood Pharmaceuticals has a consensus target price of $6.23, indicating a potential upside of 71.25%. Given Organogenesis' higher possible upside, equities research analysts plainly believe Organogenesis is more favorable than Ironwood Pharmaceuticals.

49.6% of Organogenesis shares are owned by institutional investors. 18.8% of Organogenesis shares are owned by insiders. Comparatively, 9.3% of Ironwood Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Nuvectis Pharma currently has a consensus target price of $36.25, suggesting a potential upside of 65.37%. Organogenesis has a consensus target price of $4.33, suggesting a potential upside of 225.81%. Given Organogenesis' higher probable upside, analysts plainly believe Organogenesis is more favorable than Nuvectis Pharma.

Nuvectis Pharma has a beta of -0.24, suggesting that its share price is 124% less volatile than the broader market. Comparatively, Organogenesis has a beta of 1.27, suggesting that its share price is 27% more volatile than the broader market.

Nuvectis Pharma has a net margin of 0.00% compared to Organogenesis' net margin of -19.94%. Organogenesis' return on equity of -23.89% beat Nuvectis Pharma's return on equity.

In the previous week, Nuvectis Pharma had 2 more articles in the media than Organogenesis. MarketBeat recorded 2 mentions for Nuvectis Pharma and 0 mentions for Organogenesis. Nuvectis Pharma's average media sentiment score of 0.45 beat Organogenesis' score of 0.00 indicating that Nuvectis Pharma is being referred to more favorably in the media.

96.8% of Nuvectis Pharma shares are held by institutional investors. Comparatively, 49.6% of Organogenesis shares are held by institutional investors. 28.6% of Nuvectis Pharma shares are held by insiders. Comparatively, 18.8% of Organogenesis shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Organogenesis has higher revenue and earnings than Nuvectis Pharma. Nuvectis Pharma is trading at a lower price-to-earnings ratio than Organogenesis, indicating that it is currently the more affordable of the two stocks.

MiMedx Group presently has a consensus price target of $8.57, indicating a potential upside of 86.74%. Organogenesis has a consensus price target of $4.33, indicating a potential upside of 225.81%. Given Organogenesis' higher possible upside, analysts clearly believe Organogenesis is more favorable than MiMedx Group.

MiMedx Group has a beta of 1.18, meaning that its share price is 18% more volatile than the broader market. Comparatively, Organogenesis has a beta of 1.27, meaning that its share price is 27% more volatile than the broader market.

79.2% of MiMedx Group shares are held by institutional investors. Comparatively, 49.6% of Organogenesis shares are held by institutional investors. 2.5% of MiMedx Group shares are held by insiders. Comparatively, 18.8% of Organogenesis shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

MiMedx Group has higher earnings, but lower revenue than Organogenesis. Organogenesis is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.

MiMedx Group has a net margin of 1.76% compared to Organogenesis' net margin of -19.94%. MiMedx Group's return on equity of 12.09% beat Organogenesis' return on equity.

In the previous week, MiMedx Group had 3 more articles in the media than Organogenesis. MarketBeat recorded 3 mentions for MiMedx Group and 0 mentions for Organogenesis. MiMedx Group's average media sentiment score of 0.35 beat Organogenesis' score of 0.00 indicating that MiMedx Group is being referred to more favorably in the media.

In the previous week, Sagimet Biosciences had 31 more articles in the media than Organogenesis. MarketBeat recorded 31 mentions for Sagimet Biosciences and 0 mentions for Organogenesis. Sagimet Biosciences' average media sentiment score of 0.23 beat Organogenesis' score of 0.00 indicating that Sagimet Biosciences is being referred to more favorably in the media.

87.9% of Sagimet Biosciences shares are held by institutional investors. Comparatively, 49.6% of Organogenesis shares are held by institutional investors. 11.5% of Sagimet Biosciences shares are held by company insiders. Comparatively, 18.8% of Organogenesis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Organogenesis has higher revenue and earnings than Sagimet Biosciences. Sagimet Biosciences is trading at a lower price-to-earnings ratio than Organogenesis, indicating that it is currently the more affordable of the two stocks.

Sagimet Biosciences has a beta of 3.46, suggesting that its stock price is 246% more volatile than the broader market. Comparatively, Organogenesis has a beta of 1.27, suggesting that its stock price is 27% more volatile than the broader market.

Sagimet Biosciences currently has a consensus price target of $26.63, indicating a potential upside of 191.41%. Organogenesis has a consensus price target of $4.33, indicating a potential upside of 225.81%. Given Organogenesis' higher probable upside, analysts plainly believe Organogenesis is more favorable than Sagimet Biosciences.

Sagimet Biosciences has a net margin of 0.00% compared to Organogenesis' net margin of -19.94%. Organogenesis' return on equity of -23.89% beat Sagimet Biosciences' return on equity.